Profile data is unavailable for this security.
About the company
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
- Revenue in USD (TTM)0.00
- Net income in USD-314.85m
- Incorporated2017
- Employees479.00
- LocationReplimune Group Inc500 Unicorn Park DrWOBURN 01801-3377United StatesUSA
- Phone+1 (781) 222-9600
- Fax+1 (302) 655-5049
- Websitehttps://www.replimune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 584.54m | 834.00 | -- | 1.03 | -- | 3.24 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 591.28m | 55.00 | -- | 2.96 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| ProKidney Corp | 744.00k | -71.03m | 598.66m | 204.00 | -- | -- | -- | 804.65 | -0.5443 | -0.5443 | 0.0057 | -3.41 | 0.0018 | -- | 0.2347 | 3,647.06 | -38.54 | -- | -- | -- | -- | -- | -21,403.63 | -- | -- | -- | 0.0003 | -- | -- | -- | -72.51 | -- | -- | -- |
| LB Pharmaceuticals Inc | 0.00 | -18.80m | 606.42m | 16.00 | -- | 1.95 | -- | -- | -0.82 | -0.82 | 0.00 | 12.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -905.61 | -- | -- | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 614.15m | 409.00 | -- | -- | -- | 22.40 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 624.11m | 166.00 | -- | 16.60 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -314.85m | 642.00m | 479.00 | -- | 2.94 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| Prime Medicine Inc | 5.98m | -197.34m | 648.03m | 214.00 | -- | 4.00 | -- | 108.42 | -1.44 | -1.44 | 0.0434 | 0.8975 | 0.0167 | -- | -- | 27,929.91 | -54.98 | -64.35 | -61.20 | -77.73 | -- | -- | -3,301.64 | -8,356.07 | -- | -- | 0.00 | -- | -- | -- | 1.14 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 648.77m | 15.00 | -- | 10.44 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -117.30m | 652.43m | 45.00 | -- | 3.02 | -- | -- | -2.29 | -2.29 | 0.00 | 3.22 | 0.00 | -- | -- | 0.00 | -44.05 | -- | -48.27 | -- | -- | -- | -- | -- | -- | -- | 0.1221 | -- | -- | -- | -112.73 | -- | 50.55 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -71.11m | 674.88m | 45.00 | -- | 2.79 | -- | -- | -1.14 | -1.14 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -28.80 | -35.63 | -30.41 | -38.94 | -- | -- | -- | -314.68 | -- | -- | 0.00 | -- | 2,752.05 | -- | 90.01 | -- | -20.09 | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 676.13m | 192.00 | -- | 2.79 | -- | 6.50 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
| Personalis Inc | 69.10m | -73.88m | 695.34m | 229.00 | -- | 4.05 | -- | 10.06 | -0.8761 | -0.8761 | 0.8189 | 1.93 | 0.2863 | 7.71 | 4.96 | 301,759.80 | -30.61 | -29.82 | -36.03 | -34.69 | 26.67 | 28.44 | -106.92 | -105.71 | 4.69 | -- | 0.0133 | -- | 15.15 | 5.35 | 24.94 | -- | -28.17 | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 698.87m | 111.00 | -- | 1.55 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| Gyre Therapeutics Inc | 107.27m | 6.65m | 710.76m | 574.00 | 121.15 | 6.97 | 50.41 | 6.63 | 0.0646 | 0.0646 | 1.09 | 1.12 | 0.7537 | 0.6368 | 4.73 | 186,872.80 | 8.30 | -53.99 | 12.90 | -82.36 | 95.48 | 89.58 | 11.01 | -88.61 | 5.64 | -- | 0.00 | -- | -6.78 | -- | 113.00 | -- | 117.68 | -- |
Data as of Feb 10 2026. Currency figures normalised to Replimune Group Inc's reporting currency: US Dollar USD
63.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2025 | 11.05m | 14.15% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 8.17m | 10.47% |
| RTW Investments LPas of 30 Sep 2025 | 6.40m | 8.19% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.99m | 6.39% |
| Point72 Asset Management LPas of 30 Sep 2025 | 3.63m | 4.65% |
| Tang Capital Management LLCas of 30 Sep 2025 | 3.40m | 4.36% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.29m | 4.22% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.92m | 3.75% |
| Braidwell LPas of 30 Sep 2025 | 2.75m | 3.52% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 2.63m | 3.37% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
